Loading patent…
AssigneeVirogin Biotech Canada Ltd
InventorsWilliam Wei-Guo Jia, Dmitry V. Chouljenko, I-Fang Lee, Yanal M. Murad, Xiaohu Liu, Guoyu Liu, Xuexian Bu, Zahid Delwar, Jun Ding
Estimating the term…
A herpes virus vector is provided with both transcriptional and translational control. Within various embodiments the herpes virus vector is based upon a modified herpes virus and has both ICP27 and ICP34.5 under control of a CEA promoter and miRNA-124/143, respectively, and deletion of at least one copy of terminal repeat long region is provided to increase safety without sacrificing efficacy. The herpes virus vector can also incorporate a virus-expressed cytokine cassette encoding IL-12, IL-15/IL-15RA under the control of CXCR4 promoter.
A recombinant herpes virus comprising a modified oncolytic herpes virus genome, wherein the modified herpes virus genome comprises at least one miRNA target sequence operably linked to a first copy of an ICP34.5 gene, and a second copy of the ICP34.5 gene comprises an inactivating mutation, wherein the mutation is deletion of at least one terminal repeat long region of the viral genome.
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.